CRMD | CorMedix Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	6.80 - 7.11
52 Week Range	2.5700 - 7.14
Beta	1.58
Implied Volatility	91.67%
IV Rank	22.05%
Day's Volume	700,358
Average Volume	674,548
Shares Outstanding	55,860,000
Market Cap	394,371,600
Sector	Healthcare
Industry	Biotechnology
IPO Date	2010-05-13

Valuation
Profitability
Growth
Health
P/E Ratio	-7.67
Forward P/E Ratio	-4.34
EPS	-0.92
1YR Price Target	14.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	82
Country	USA
Website	CRMD

Cormedix Inc is a biopharmaceutical company that focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. It has been in-licensed to develop and commercialize Neutrolin, which is a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings such as hemodialysis, total parenteral nutrition, and oncology. The Neutrolin product is designed to target unmet medical needs.

CRMD's peers: TARS, LIAN, ALDX, TVTX, ETON, PGEN, TCRR, SGMO, APTO, ELYM, INBX, MACK, CELC, ELVN, REPL, NVCT, LYRA, KRON, GOSS, CNTB, ABOS, NUVB, ELDN

*Chart delayed

Analyzing fundamentals for CRMD we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see CRMD Fundamentals page.

Watching at CRMD technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on CRMD Technicals page.